DrugPatentWatch Database Preview
Glaxo Grp England Company Profile
What is the competitive landscape for GLAXO GRP ENGLAND, and what generic alternatives to GLAXO GRP ENGLAND drugs are available?
There are ten US patents protecting GLAXO GRP ENGLAND drugs.
There are one hundred and forty-five patent family members on GLAXO GRP ENGLAND drugs in thirty-nine countries and fourteen supplementary protection certificates in eleven countries.
Summary for Glaxo Grp England
| International Patents: | 145 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Glaxo Grp England
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,161,968 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,183,257 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Glaxo Grp England
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | 5,873,360 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Non-Orange Book US Patents for Glaxo Grp England
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 9,045,469 | Muscarinic acetylcholine receptor antagonists | ➤ Sign Up |
| 9,144,571 | Muscarinic acetylcholine receptor antagonists | ➤ Sign Up |
| 8,575,347 | Muscarinic acetylcholine receptor antagonists | ➤ Sign Up |
| 8,853,404 | Muscarinic acetylcholine receptor antagonists | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Glaxo Grp England Drugs
Supplementary Protection Certificates for Glaxo Grp England Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2014038,C1740177 | Lithuania | ➤ Sign Up | PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428 |
| 90060-9 | Sweden | ➤ Sign Up | PRODUCT NAME: UMECLIDINIUM BROMIDE; REG. NO/DATE: EU/1/14/922 20140428 |
| 0694 | Netherlands | ➤ Sign Up | PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430 |
| 00694 | Netherlands | ➤ Sign Up | PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
